Logo

Sanofi's Dupixent (dupilumab) Receives Health Canada Approval as the First Biologic to Treat Atopic Dermatitis in Children

Share this

Sanofi's Dupixent (dupilumab) Receives Health Canada Approval as the First Biologic to Treat Atopic Dermatitis in Children

Shots:

  • Health Canada has approved Dupixent for the treatment of mod. to sev. AD in children aged 6 to 11yrs. whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable
  • The approval marks the fifth indication for Dupixent in Canada following the approvals for AD in adults and adolescents- severe chronic rhinosinusitis with nasal polyposis- and severe asthma in adults and adolescents
  • The results from a survey in Canadian children showed 70% experienced the loss of sleep and 30% experienced anxiety. Dupixent is a mAb targeting IL-4 and IL-13 proteins and is not an immunosuppressant

 ­ Ref: Newswire Canada | Image: Global Competition Review

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions